Lipid Nanoparticles in mRNA Vaccine Delivery

How do lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccine antigens?

Lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines by encapsulating the mRNA through electrostatic and hydrogen bonding interactions, facilitating cellular uptake via endocytosis, and releasing the mRNA into the cytoplasm when ionizable lipids protonate in acidic endosomes and disrupt the endosomal membrane to enable translation.

Abstract

Lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines through a coordinated physicochemical and biological process. LNPs composed of ionizable lipids, helper lipids, cholesterol, and PEG-lipids form 50-85 nm particles that encapsulate mRNA via electrostatic interactions and hydrogen bonding. Following intramuscular administration, LNPs are taken up by muscle-resident immune cells through endocytosis, with >10% of myeloid and lymphoid cells successfully transduced. The critical delivery step occurs when ionizable lipids protonate in acidic endosomes (pH ~5-6), triggering ion pairing with endosomal phospholipids that disrupts membranes and releases mRNA into the cytoplasm. Nucleoside modifications such as m1ψ reduce innate immune recognition of the mRNA cargo, while optimized formulations achieve 93-95% encapsulation efficiency and mRNA detectability for 14-28 days post-vaccination in humans.

Beyond mRNA delivery, LNPs function as intrinsic adjuvants by triggering rapid neutrophil and dendritic cell recruitment within 24 hours and inducing IL-6 production critical for germinal center responses. This dual functionality produces potent immunogenicity, with optimized formulations achieving 10-fold higher neutralizing titers than standard LNPs and protective immunity at doses as low as 0.25 µg. Rational lipid design enables independent control of delivery efficiency, tissue targeting, immune activation, and stability: the C24 formulation reduces off-target liver expression 6-fold while maintaining potency, adjuvant lipidoids provide TLR7/8 activation, and specific formulations remain stable at 4°C for at least 19 days. These mechanisms collectively explain the exceptional clinical efficacy of LNP-mRNA SARS-CoV-2 vaccines.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

LNP Composition:

• Ionizable lipid type and concentration
• Helper lipids (DSPC, cholesterol, etc.) and ratios
• PEG-lipid type and percentage
• Novel or modified lipid components
• Design rationale for each component
• Particle size and polydispersity
• Formulation buffer and pH conditions

mRNA Specifications:

• Target antigen (spike protein variants, epitopes, etc.)
• Specific nucleoside modifications (pseudouridine, 5-methylcytidine, etc.)
• mRNA sequence length and structure
• Cap structure and poly-A tail details
• Codon optimization strategies
• mRNA-to-lipid ratios in formulation

Cellular Uptake Mechanism:

• Cell types that take up LNPs (muscle cells, APCs, etc.)
• Uptake pathways (endocytosis, fusion, etc.)
• Endosomal escape mechanisms
• Role of ionizable lipids in pH-dependent release
• Timeline from uptake to protein expression
• Subcellular trafficking patterns
• Membrane interaction studies

Delivery Efficiency:

• Protein expression levels (luciferase, spike protein)
• Transfection efficiency percentages
• Duration of protein expression
• Dose-response relationships
• Comparison with control formulations
• In vitro vs in vivo delivery efficiency
• Target tissue specificity

Structural Properties:

• LNP morphology (core-shell, solid core, etc.)
• mRNA-lipid interaction patterns
• Hydrogen bonding or ionic interactions
• Membrane organization (bilayer, monolayer)
• Mechanical properties (elasticity, compliance)
• Surface charge and zeta potential
• Cryo-TEM or AFM structural observations

Biodistribution Pattern:

• Primary target tissues (muscle, liver, spleen, etc.)
• Distribution kinetics and timeline
• Off-target expression levels
• Route of administration effects
• Factors controlling tissue targeting
• Methods used to track biodistribution
• Clearance mechanisms and timeline

Inflammatory Effects:

• Innate immune responses triggered by LNPs
• Inflammatory cytokine induction
• Neutrophil and dendritic cell recruitment
• Local vs systemic inflammation
• Adjuvant effects of lipid components
• TLR activation pathways
• Injection site reactogenicity
• Timeline of inflammatory responses

Stability Factors:

• Storage temperature requirements
• mRNA integrity maintenance
• LNP structure preservation
• Bioactivity retention timeline
• Mechanisms of degradation
• Formulation stability enhancers
• Real-time vs accelerated stability data
• Impact on delivery efficiency

Results

Characteristics of Included Studies

Each of the 10 studies investigated lipid nanoparticle delivery systems for nucleoside-modified mRNA encoding SARS-CoV-2 spike protein antigens. Seven studies had full text available. The studies employed diverse approaches including novel lipid development, structural characterization, immunogenicity testing in animal models, and clinical pharmacokinetic analysis in humans.

LNP Composition and Formulation Design

LNP formulations for SARS-CoV-2 mRNA delivery consist of four core lipid components: ionizable lipids, helper lipids, cholesterol, and PEG-lipids. The ionizable lipid component is crucial for mRNA complexing and pH-dependent release.

mRNA Cargo Characteristics

The nucleoside-modified mRNA cargo encoded the SARS-CoV-2 spike protein with specific structural modifications. The target antigens included full-length spike protein with deleted furin cleavage site, diproline-stabilized spike protein, and prefusion-stabilized spike with two proline mutations.

Cellular Uptake and Delivery Mechanisms

LNPs deliver mRNA through a multi-step process involving cellular uptake, endosomal escape, and cytoplasmic release. The ionizable lipids play a central role in pH-dependent delivery.

Delivery Efficiency and Protein Expression

Quantitative delivery efficiency varied across formulations, with several showing superior performance compared to standard formulations.

Biodistribution Patterns

Following intramuscular administration, LNPs demonstrated specific biodistribution kinetics with varying degrees of systemic exposure.

Immune Activation and Adjuvant Properties

Beyond mRNA delivery, LNPs demonstrated intrinsic adjuvant activity contributing to robust immune responses.

Stability and Storage Considerations

LNP-mRNA stability depended critically on storage temperature and formulation design.

Synthesis

The mechanisms by which lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines involve an integrated series of physicochemical and biological processes. The delivery cascade initiates with formulation design, where ionizable lipids complex with negatively charged mRNA through electrostatic and hydrogen bonding interactions. Following intramuscular administration, LNPs interact with muscle cells and immune cells through endocytic uptake, with >10% of muscle-resident myeloid and lymphoid cells successfully transduced.

The critical endosomal escape step relies on pH-dependent protonation of ionizable lipids in acidic endosomes, triggering membrane disruption through ion pairing with endosomal phospholipids. Different ionizable lipids achieve this through distinct mechanisms: the C24 formulation employs multistage protonation, while adjuvant lipidoids enhance escape through TLR7/8 receptor engagement. Upon cytoplasmic release, the nucleoside-modified mRNA is translated by cellular ribosomes to produce spike protein antigen.

Beyond simple mRNA delivery, LNPs function as adjuvants by triggering innate immune responses. Empty LNPs alone elicit neutrophil and dendritic cell recruitment within 24 hours, while the ionizable lipid component induces IL-6 production critical for germinal center formation. This dual functionality—mRNA delivery plus immune activation—underlies the exceptional efficacy of LNP-mRNA SARS-CoV-2 vaccines, with some formulations achieving protection at doses as low as 0.25 µg and neutralizing titers 10-fold higher than conventional formulations.